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E-mail address: amwu@mail.cgu.edu.tw (A.M. WuFor the GalNAca1? speciﬁc Agaricus bisporus agglutinin (ABA) from an edible mushroom, the mech-
anism of polyvalent Galb1?3/4GlcNAcb1? complex in ABA–carbohydrate recognition has not been
well deﬁned since Gal and GlcNAc are weak ligands. By enzyme-linked lectinosorbent and inhibition
assays, we show that the polyvalent Galb1?3/4GlcNAcb1? in natural glycans also play vital roles in
binding and we propose that four different intensities of glycotopes (Galb1-3GalNAca1-, GalNAca1-
Ser/Thr and Galb1-3/4GlcNAcb1-) construct three recognition systems at the same domain. This pecu-
liar concept provides the most comprehensive mechanism for the attachment of ABA to target gly-
cans and malignant cells at the molecular level.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The Agaricus bisporus agglutinin (ABA) in edible mushroom has
been found to have a potent anti-proliferative effect on malignant
colon cells with considerable therapeutic potential as an anti-
neoplastic agent [1–3]. This lectin has a molecular mass of
6.4  104 Da and consists of four apparently identical subunits
(Mr. 16 000) [4]. Previous studies on the structural requirements
for glyco-recognition of ABA were focused on GalNAca1-related
ligands at reducing ends of O-glycans [5]. It was also found that
multi-complex N-glycans may be involved in glyco-recognition,
while Gal, Man and GlcNAc were weak or inactive binders. To fur-
ther clarify the mechanisms of multi-complex N-glycans in ABA–
carbohydrate recognition process, the inhibition of ABA–complex
N-glycan (asialo human a1-acid glycoprotein) binding was evalu-
ated. In contrast to the previous reports, the results revealed that
the inactive Galb1-related ligands and its cluster features of mul-
ti-antennary IIb (Galb1-4GlcNAcb1-) in N-glycans also play a vital
role in binding. Thus, three recognition systems of four different
intensities of mammalian structural units (glycotopes) involved
in ABA–glycan interactions at the same combining site or two
nearby sites within the same domain are deﬁned. The four differ-
ent structural units are: Galb1-3GalNAca1- glycotope (Ta, most
active one), GalNAca1-Ser/Thr (Tn), Galb1-3GlcNAcb1- (Ib) andchemical Societies. Published by E
).Galb1-4GlcNAcb1- (IIb); the three recognition systems are – Ta
for O-glycan, Tn for O-glycans and Ib/IIb for O/N-glycans and Pneu-
mococcus type 14 capsular polysaccharides; the order of potency of
glycotopes is Ta > Tn, Ib IIb; polyvalency is essential for all inter-
actions. This hypothesis provides the most comprehensive concept
to explain the ability of ABA to recognize target glycans and malig-
nant cells at the molecular level [5–7]. Furthermore, through this
study, the current structural concept of the combining sites of lec-
tins has also been expanded. It is expected that this approach can
also be applied to many other lectins.
2. Materials and methods
2.1. Lectin preparation and biotinylation
Agaricus bisporus agglutinin (ABA) was purchased from Sigma
Chemical Co., (St. Louis, MO, USA). Lectin biotinylation was per-
formed as described previously [8,9].
2.2. Glycoproteins and polysaccharides
The blood group precursors and Smith-degraded products (e.g.,
cyst Mcdon P-1, Tighe P-1 and cyst JS 1st Smith degraded) were
puriﬁed and prepared from human ovarian cyst ﬂuid [10–12]. Hu-
man/bovine a1-acid gps, and fetuin, which are multi-antennary IIb
containing N-glycans [13], were purchased from Sigma Chemical
Co. (St. Louis).lsevier B.V. All rights reserved.
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dibular mucins (BSM, PSM and OSM), were puriﬁed according to
the procedure of Tettamanti and Pigman [14] and its modiﬁcations
[14–16].
Desialylation of sialoglycoproteins was performed by mild acid
hydrolysis in 0.01 N HCl at 80 C for 90 min and followed by dial-
ysis against distilled H2O for 2 days to remove small fragments
[14,15].
Pneumococcus type XIV and Gala1?4Gal containing Okra poly-
saccharides were prepared as described previously [17,18]. Man-
nan isolated from yeast, Saccharomyces cerevisiae, which consists
of complex DMan with a1,6 linkage on backbone and a1,2/a1,3
linkages on side chains [19,20]. Poly-2,8-N-acetylneuraminic acid
capsular polysaccharide (colominic acid) from Escherichia coli
[21] were purchased from Sigma Chemical Co. (St. Louis).
2.3. Monosaccharides and oligosaccharides
Mono-, di- and oligosaccharides were either purchased from
Sigma Chem. Co. (USA) or prepared by Dextra (Reading, Berkshire,
UK).
2.4. Lectin–enzyme binding assays (ELLSA)
The assays were performed according to the procedures de-
scribed by Duk et al. [8]. The volume of each reagent solution ap-
plied to wells of the plate was 50 ll/well, and all incubations,
except for coating, were performed at 20 C. The reagents, if not
indicated otherwise, were diluted with TBS containing 0.05%
Tween 20 (TBS-T) and TBS-T was used to wash plates between
incubations. For inhibition studies, serially diluted inhibitor sam-
ples were mixed with ﬁxed amount of biotinylated ABA. The con-
trol lectin sample was diluted twofold with TBS-T. After 30 min
incubation at 20 C, the samples were tested by using the bindingTable 1
Binding of ABA to human blood group active, sialo-, asialo-glycoproteins and polysacchar
Sample No. (#) Glycoprotein (lectin determinantsb; blood group speciﬁcity)
N-Glycans
1 Asialo bovine a1-acid gp (IIb)
2 Asialo fetuin (IIb > Ib, Ta)
3 Fetuin (sialyl IIb, Ta)
4 Asialo human a1-acid gp (IIb)
5 Bovine a1-acid gp (sialyl IIb)
6 Human a1-acid gp (sialyl IIb)
O-Glycans
7 Cyst Mcdon P-1 (Ib, IIb, Ta, Tn)
8 Cyst Tighe P-1 (Ib, IIb, Ta, Tn)
9 Cyst Beach P-1 (Ib, IIb, Ta, Tn)
10 Asialo BSM (Tn, GlcNAcb1?3Tn)
11 Cyst JS 1st Smith degraded (Ib, IIb, Ta, Tn)
12 BSM (sialyl Tn, GlcNAcb1?3Tn)
13 Asialo PSM (Ta, Tn, Ah, H)
14 Asialo OSM (Tn)
15 PSM (sialy Ta, Tn)
16 OSM (sialyl Tn)
Polysaccharides
17 Pneumococcus type 14 ps (repeating units of IIb)
18 Mannane
19 Okrae (poly Gala1-4Gal)
20 Colominic acide (poly Neu5Aca2-8Neu5Ac)
a 10 ng of biotinylated lectin were added to various gps, ranging from 0.016 ng to 5 l
b The bolded symbols in parentheses indicates the human blood group activity and/or
(LFuca1-2Gal); Ta (Galb1-3GalNAca1-); Tn (GalNAca1-Ser/Thr); Ib/IIb (Galb1-3/4GlcNAc
c The results were interpreted according to the measured A405 after 2 h incuba
(1.5 > O.D.P 1.0), + (1.0 > O.D.P 0.5), ± (0.5 > O.D.P 0.2), and  (O.D. < 0.2).
d According to [5].
e Negative control.assay [8,9]. The inhibitory activity was estimated from the inhibi-
tion curve and is expressed as the amount of inhibitor (ng per well)
giving 50% inhibition of the control ABA binding.
3. Results
3.1. Interaction of ABA with diverse glycoproteins and polysaccharides
The avidities of ABA to various glycoproteins and polysaccha-
rides were analyzed by a microtiter plate enzyme-linked lectino-
sorbent assay (ELLSA). The interaction intensities are summarized
in Table 1. Among the polyvalent glycotopes tested, ABA reacted
strongly with Ta/Tn-containing O-glycans (#12 to #16), Ib or IIb-
containing O-glycans (#7 to #9, #11), IIb-containing N-glycans
(#1 to #6) and with Pneumococcus type 14 ps of repeating unit of
IIb (#17), but not other polysaccharides (#18 to #20). These results
indicate that polyvalent IIb structural units in complex N-glycans
and in high density polyforms (Pneumococcus type 14 capsular
ps, #17) are ascertainably one of the recognition factors in ABA rec-
ognition process.
3.2. Inhibition of ABA – IIb-containing N-glycan (asialo human a1-acid
gp) recognition by N-glycans, O-glycans and other polysaccharides
In order to conﬁrm that ABA binding to complex N-glycans is
glyco-speciﬁc, the ABA interaction with asialo human a1-acid gp
(N-glycan) was inhibited by various N-gycans, O-glycans and other
glycans and expressed as 50% mass (nanogram) inhibition. As
shown in Table 2, all O-glycans (#7 to #14) were very active li-
gands and up to 4.1  105-fold as active as GalNAc (#15) and all
N-glycans (#1 to #6) were also active ligands and up to
2.0  104-fold as active as GalNAc. These results suggest that poly-
valent Galb1?3/4GlcNAc (Ib/IIb) can be assigned as one of the ABA
recognition systems.ides by ELLSA.a
1.5 (A405) unit (ng) Maximum A405 absorbance
Absorbance reading Binding intensityc
2.5 4.4 5+
3.0 2.7d 5+
4.5 3.0d 5+
7.0 3.0d 5+
26.0 2.3 4+
200.0 2.3d 4+
0.3 4.4 5+
0.4 3.0d 5+
0.7 3.0d 5+
0.8 4.0 5+
1.0 3.0d 5+
10.0 3.6 5+
11.0 3.0d 5+
17.0 3.0d 5+
20.0 1.7d 3+
50.0 2.0d 4+
110.0 2.2d 4+
 0.1d 
 0.1 
 d 
g.
lectin determinants [23–26]: A (GalNAca1-3Gal); Ah (GalNAca1-3[LFuca1-2]Gal); H
b1-).
tion as follows: 5+ (O.D.P 2.5), 4+ (2.5 > O.D.P 2.0), 3+ (2.0 > O.D.P 1.5), 2+
Table 2
Amount of various glycoproteins and saccharides giving 50% inhibition of ABA (10 ng/50 ll) binding to a IIb-containing complex N-glycan (asialo human a1-acid gp, 20 ng/50 ll).a
Sample No. (#) Inhibitorb Quantity giving 50% inhibition (ng) Relative potencyc
N-Glycans
1 Asialo bovine a1-acid gp (IIb) 42.0 2.0  104
2 Asialo fetuin (IIb > Ib, Ta) 46.5 1.7  104
3 Asialo human a1-acid gp (IIb) 137.0 5.9  103
4 Bovine a1-acid gp (sialy IIb) 340.0 2.3  103
5 Fetuin (sialy IIb, Ta) 440.0 1.8  103
6 Human a1-acid gp (sialy IIb) 840.0 9.6  102
O-Glycans
7 Asialo BSM (sialyl Tn, GlcNAcb1?3Tn) 2.0 4.1  105
8 Cyst Mcdon P-1 (Ta, Tn, Ib, IIb) 2.0 4.1  105
9 Asialo PSM (Ta, Tn, Ah, H) 2.5 3.2  105
10 Cyst JS 1st Smith degraded (Ib, IIb, Ta, Tn) 5.0 1.6  105
11 Asialo OSM (Tn) 10.0 8.0  104
12 BSM (sialyl Tn, GlcNAcb1?3Tn) 16.5 4.8  104
13 PSM (sialyl Ta, Tn) 36.0 2.3  104
14 OSM (sialyl Tn) 175.0 4.6  103
Monosaccharides and polysaccharides
15 GalNAc 8.0  105 1.0
16 Gal >5.0  106 (4.4% inhibition) –
17 GlcNAc >3.8  106 (8.4% inhibition) –
18 Man >5.0  106 (13.0% inhibition) –
19 Mannan >2.8  103 (3.5% inhibition) –
a The inhibitory activity is expressed as the amount of inhibitor (nanogram) giving 50% inhibition. Total volume is 50 ll.
b The symbol in parentheses indicates the human blood group activity and/or lectin determinants [23–26]. Expressed in bold are: A (GalNAca1-3Gal); Ah (GalNAca1-
3[LFuca1-2]Gal); H (LFuca1-2Gal); Ta (Galb1-3GalNAca1-); Tn (GalNAca1-Ser/Thr); Ib/IIb (Galb1-3/4GlcNAcb1-).
c Relative potency (RP) = Quantity of GalNAc required for 50% inhibition is taken as 1.0/Quantity of sample required for 50% inhibition. The concentration was 2.8  102 ng
for non-reactive polysaccharides (Okra and Colominic acid).
Table 3
Amount of glycoproteins giving 50% inhibition of ABA (2.5 ng/50 ll) by asialo PSM (5 ng/50 ll).a,b
Sample No. Inhibitor (multivalent structural units) Quantity giving 50% inhibition (ng) Relative potencyc
1 Asialo PSM (Ta, Tn, Ah, H) 0.07 4.7  106
2 Cyst Tighe P-1 (Ib, IIb, Ta, Tn) 0.4 8.3  105
3 Asialo OSM (Tn) 3.0 1.1  105
4 PSM (sialyl Ta, Tn) 10.0 3.3  104
5 OSM (sialyl Tn) 20.0 1.7  104
6 Asialo human a1-acid gp (mIIb) 22.0 1.5  104
7 Pneumococcus type 14 ps (IIb) 110.0 3.0  103
8 Human a1-acid gp (sialyl mIIb) 200.0 1.7  103
9 Galb1-3GalNAc (T) 3.8  104 8.7
10 Galb1-3GlcNAc (I) 1.1  105 3.0
11 GalNAc 3.3  105 1.0
12 Galb1-4Glc (L) 5.1  105d 0.6
13 GlcNAc 4.0  107d 0.008
14 Man >2.2  106e <0.15
15 Glc >3.8  106e <0.09
16 Gal >4.0  106e <0.08
17 Mannan >277.8 (18.3% inhibition) –
18 Galb1-4GlcNAc (II) >2.5  105 (5.1%inhibition) –
a Adopted from part of Tables 2 and 3 [5].
b The inhibitory activity is expressed as the amount of inhibitor giving 50% inhibition of the control lectin binding. Total volume is 50 ll.
c Relative potency (RP) = Quantity of GalNAc required for 50% inhibition is taken as 1.0/Quantity of sample required for 50% inhibition.
d Extrapolation.
e Maximum amount of inhibitor tested.
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recognition by N-glycans, O-glycans and other polysaccharides
ABA – Ta/Tn-containing O-glycan (asialo PSM) inhibition assay
was repeated to establish the location of the combining site of
ABA for O-glycans and complex N-glycans (polyvalent IIb glyco-
topes). As summarized in Table 3, Ta/Tn-containing O-glycans
(#1, #3 to #5); IIb-containing complex N- and/or O-glycans (#2,
#6 and #8) and Pneumococcus type 14 polysaccharides (#7)
strongly inhibit the interaction, demonstrating that four active gly-
cotopes – GalNAca1-Ser/Thr (Tn), Galb1-3GalNAca1- (Ta) and
Galb1-3/4GlcNAcb1- (Ib/IIb), share the same combining site (Struc-
ture 1) or nearby sites.4. Discussion
In human diet, there are many lectins that resist heat and diges-
tion [1]. In colon and faeces, these lectins remain in active form
with notable effects on the function of gastrointestinal cells
[1,3,4,22]. Agaricus bisporus agglutinin (ABA) isolated from edible
mushroom is one of the dietary lectins that possesses considerable
therapeutic potential with potent anti-proliferative effects and is
an anti-neoplastic agent toward malignant colon cancer cells
[1,3,4]. Previous studies on the structural requirements for ABA
glyco-recognition were focused on GalNAc related ligands
(Ta, Galb1-3GalNAca1-; Tn, GalNAca1-Ser/Thr) in O-glycans and
analyzed by enzyme-linked lectinosorbent/inhibition assays [5].
Structure 1. Four different intensities of mammalian glycotope units (i–iv) constructing three recognition systems (i–iv) for Agaricus bisporus agglutinin–glycan interactions.
3564 A.M. Wu et al. / FEBS Letters 584 (2010) 3561–3566It was also found that many complex N-glycans may also be in-
volved in glyco-recognition, while Gal, Man and GlcNAc were weak
or inactive ligands. Later, roles of GlcNAc-exposed N-glycans were
studied by lectin microarray and frontal afﬁnity chromatography
[7] and the existence of another independent carbohydrate-bind-
ing site for GlcNAc in glycans was reported [6]. In order to further
clarify these observations, natural glycoproteins were used to elu-cidate the polyvalent effects of weak Galb1?4GlcNAcb (IIb) and
weak Galb1?3GlcNAcb (Ib) in N-glycan on the recognition process.
To eliminate the possibility of non-speciﬁc interactions, the roles of
complex N-glycans in ABA–glycan recognition process were fur-
ther studied by the inhibition approach, in which ABA – complex
N-glycan (asialo human a1-acid glycoprotein) rather than O-glycan
(asialo PSM) interaction system [5] was used in this study. The
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cans tested can inhibit not only ABA–O-glycan interactions, but
also ABA–N-glycan interactions. Thus, it is proposed that the com-
bining site of ABA consists of one major site (a potent –OH conﬁg-
uration of GalNAc for Tn and Ta or –OH conﬁguration of a weak
GlcNAcb1?for Ib and IIb) and two subsites (Galb1-3/4 at non-
reducing end) for accommodating four different intensities of
mammalian glycotopes and three recognition systems (Tn, Ta
and Galb1-3/4GlcNAcb1-). When the inactive Gal is b1-3 linked
to GalNAca1- (Tn) at non-reducing end, the Galb1-3GalNAca1-
(Ta, the most active glycotope) sequence is formed. GlcNAc is a
very poor monosaccharide inhibitor (#13 in Table 3) and different
from GalNAc at the –OH conﬁguration at carbon-4. Combination of
these two weak or inactive monosaccharides (Gal and GlcNAc) by
b1-3/4 linkages as Ib/IIb (Galb1-3GlcNAcb1-/Galb1-4GlcNAcb1-) re-
sulted in a greater than 360 times enhancement of binding (#10,
Galb1-3GlcNAcb1- vs. #13, GlcNAc in Table 3). The glycotopes of
Ib and IIb (Galb1-3/4GlcNAcb1-) existing in both O- and N-glycans
are constructed as the third recognition system. Since the results of
both inhibition proﬁles (Tables 2 and 3) were similar, in which
intensity of polyvalent Ta/Tn were more potent than polyvalent
Ib/IIb (#7, #9, #11 to #14 vs. #1 to #6 in Table 2; #1 and #3 vs.
#6 and #7 in Table 3). These active glycotopes – GalNAca1-Ser/
Thr (Tn), Galb1-3GalNAca1- (Ta) and Galb1-3/4GlcNAcb1- (Ib/IIb)
are proposed to share the same combining site through three dif-
ferent recognition systems (Structure 1). Its size should be as large
as disaccharide and most complementary to Galb1-3GalNAca1-
(Ta). If ‘‘two intrinsic sugar-binding sites in one polypeptide; one
for Ta and the other for GlcNAc” suggested by Nakamura-Tsuruta
[6,7] exist, the inhibitory proﬁles, as shown in the Tables 2 and 3,
would be expected to be different. Therefore, it is proposed that
the GalNAc and GlcNAc should share the same major site and also
conﬁguration of carbons-2, -3 and -5. Otherwise, they must be lo-
cated at nearby sites.
During the past three decades, many synthetic glycans or li-
gands have been used to study the binding properties of lectins
or antibodies, especially in the worldwide consortium systems.
However, these interactions are not in existence in nature. In this
study, all the polyvalent glycoforms used in this study were from
natural sources, which clearly demonstrated the theme of our
study (Tables 2 and 3).
The combining site of antibodies has been proposed to be di-
vided into only two shapes: the cavity and the groove type by Ka-
bat [27]. Based on our three decades of study, the combining sites
of most lectins appear to be more complicated than Kabat pro-
posed. Recently, we found that different intensities of four mam-
malian structural units constructing four recognition systems at
two different combining sites for the process of Ralstonia solana-
cearum lectin–glycan interactions (unpublished data) [29] in which
the inhibitory proﬁles are very different. In addition to our current
report on ‘‘duality of the carbohydrate-recognition system of
Pseudomonas aeruginosa-II lectin (PA-IIL)” sharing the same conﬁg-
urations of epimeric –OH at carbon -2, and -4 of LFuc for both
LFuc-containing glycans and mannan recognition [28]. Now, at least
three types – cavity, groove and hybrid types (cavity as major site
and groove as subsite) are frequently found in plant lectins. Better
systems are being explored and organized in our laboratory for
plant, microbial and animal lectins. From the results of this study,
the Kabat’s structural concept of the combining site of lectins has
been expanded and upgraded [28]. It is expected that this approach
and concept can be applied to other lectin recognition systems.
Combining previous and current results [5–7], it is proposed
that: (a) the combining site of ABA is composed of one major site
a potent –OH conﬁguration of GalNAc and a weak –OH conﬁgura-
tion of GlcNAc i.e. GalNAc GlcNAc and two subsites (Galb1-3/4)
at non-reducing end for ﬁtting four different intensities of glyco-topes and three recognition systems (Tn, Ta and Galb1-3/4Glc-
NAc); (b) the order of potency of glycotope units is Ta > Tn,
Ib > IIb; (c) polyvalency is essential for all interactions; (d) the order
of the intensities of polyvalency enhancement, opposing to that of
(b), is approximately IIb > Ib > Tn Ta; (e) the combining size of
ABA should be as large as disaccharide and most complementary
to Ta; (f) the sites for all glycotope units are located at the same
site or nearby sites as an independent GlcNAc subsite has been re-
ported [6,7]. Thus, an additional recognition factor responsible for
the polyvalent effect of a poor Galb1?4GlcNAcb (IIb) and a weak
Galb1?3GlcNAcb (Ib) on N-glycan–ABA interactions was estab-
lished. The peculiar concept of four different intensities of glyco-
tope units constructing three recognition systems provides an
advanced knowledge about the combining sites of ABA, which
can be used to explain the ABA attachment process to target gly-
cans or malignant cells at the molecular level.
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